United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineering of disease-associated macrophages and dendritic cells, today announced the acquisition of multiple assets from Carisma Therapeutics Inc..

United Immunity plans to leverage these innovative assets in combination with its PEG-free, pullulan-coated lipid nanoparticle (P-LNP) delivery system to generate in vivo CAR-M and other genetically engineered macrophages. This integrated approach aims to advance next-generation therapies for solid tumors and fibrosis diseases.

“Both assets has novel technologies to boost the efficacy of in vivo engineered anti-tumor or anti-fibrotic macrophages,” said Masato Kishida, Chief Executive Officer of United Immunity. “Our in vivo CAR-M therapy boosted by these proprietary assets represent a promising therapeutic approach for patients with solid tumors. In addition, United Immunity’s active targeting in vivo CAR-M strategy may provide an improved safety profile by reducing the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which are frequently associated with CAR-T cell therapies.”